Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Sooreshjani MA, Nikhil K, Kamra M, et al. LIMK2-NKX3.1 engagement promotes castration-resistant prostate cancer. Cancers (Basel). 2021;13(10):2324.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–380.
   PubMed Web of Science ®Google Scholar
• Guerrero J, Alfaro IE, Gómez F, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12):1291–1305.
   PubMed Web of Science ®Google Scholar
• Shah N, Wang P, Wongvipat J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:e27861.
   Web of Science ®Google Scholar
• Chou FJ, Lin C, Tian H, et al. Preclinical studies using cisplatin/carboplatin to restore the enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress enzalutamide resistant prostate cancer. Cell Death Dis. 2020;11(11):942.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038.
   PubMed Web of Science ®Google Scholar
• Jin Z, Yi X, Yang J, et al. Liposome-coated Arsenic-manganese complex for magnetic resonance Imaging-Guided synergistic therapy against carcinoma. Int J Nanomedicine. 2021;16:3775–3788.
   PubMed Web of Science ®Google Scholar
• Abudoureyimu A, Muhemaitibake A. Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP. Eur Rev Med Pharmacol Sci. 2017;21(3):612–617.
   PubMed Web of Science ®Google Scholar
• Jutooru I, Chadalapaka G, Sreevalsan S, et al. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 2010;316(13):2174–2188.
   PubMed Web of Science ®Google Scholar
• Lu M, Xia L, Luo D, et al. Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene. 2004;23(22):3945–3952.
   PubMed Web of Science ®Google Scholar
• Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001;61(14):5432–5440.
   PubMed Web of Science ®Google Scholar
• Ji H, Li Y, Jiang F, et al. Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. Cancer Sci. 2014;105(12):1541–1549.
   PubMed Web of Science ®Google Scholar
• Rosenblatt AE, Burnstein KL. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol. 2009;23(3):412–421.
   PubMedGoogle Scholar
• Li L, Karanika S, Yang G, et al. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479.
   Web of Science ®Google Scholar
• Mirzaei A, Rashedi S, Akbari M, et al. Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. J Cell Mol Med. 2022;26(9):2728–2740.
   PubMed Web of Science ®Google Scholar
• Feng T, Wei D, Zhao J, et al. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes. Exp Biol Med. 2021;246(15):1776–1787.
   Web of Science ®Google Scholar
• Li C, Wang Y, Zhang H, et al. An investigation on the cytotoxicity and caspase-mediated apoptotic effect of biologically synthesized gold nanoparticles using cardiospermum halicacabum on AGS gastric carcinoma cells. Int J Nanomedicine. 2019;14:951–962.
   PubMed Web of Science ®Google Scholar
• Karanika S, Karantanos T, Li L, et al. Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6ATR-Chk1 signaling. Cell Rep. 2017;18(8):1970–1981.
   PubMed Web of Science ®Google Scholar
• Li L, Chang W, Yang G, et al. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014;7(326):ra47.
   PubMed Web of Science ®Google Scholar
• Luo Y, Li M, Zuo X, et al. β‑Catenin nuclear translocation induced by HIF‑1α overexpression leads to the radioresistance of prostate cancer. Int J Oncol. 2018;52(6):1827–1840.
   PubMed Web of Science ®Google Scholar
• Liu B, Sun Y, Tang M, et al. The miR-361-3p increases enzalutamide (enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the enz-resistant prostate cancer. Cell Death Dis. 2020;11(9):807.
   PubMed Web of Science ®Google Scholar
• Srinivas US, Tan BWQ, Vellayappan BA, et al. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084.
   PubMed Web of Science ®Google Scholar
• Ide H, Lu Y, Yu J, et al. Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines. Prostate. 2012;72(13):1407–1411.
   PubMed Web of Science ®Google Scholar
• Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134–1149.
   PubMed Web of Science ®Google Scholar
• Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–467.
   PubMed Web of Science ®Google Scholar
• Xiao YF, Liu SX, Wu DD, et al. Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. World J Gastroenterol. 2006;12(36):5780–5786.
   PubMed Web of Science ®Google Scholar
• Yang MH, Chang KJ, Zheng JC, et al. Anti-angiogenic effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, proliferation and tube formation. Oncol Lett. 2017;14(3):3103–3109.
   PubMed Web of Science ®Google Scholar
• Yang MH, Zang YS, Huang H, et al. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets. 2014;14(6):557–566.
   PubMed Web of Science ®Google Scholar
• Carney DA. Arsenic trioxide mechanisms of action–looking beyond acute promyelocytic leukemia. Leuk Lymphoma. 2008;49(10):1846–1851.
   PubMed Web of Science ®Google Scholar
• Luo Y, Azad AK, Karanika S, et al. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer. 2018;142(10):2163–2174.
   PubMed Web of Science ®Google Scholar